DEMELA™

DEMELA™ is a patented peptide-based brightening technology developed to cosmetically support a more even, luminous skin tone in cases of hyperpigmentation, post-inflammatory discoloration, and visible redness.

Designed for use in professional and advanced skincare formulations, DEMELA™ targets melanin overproduction at multiple regulatory levels of the melanogenesis pathway, helping improve skin clarity while maintaining comfort, hydration, and barrier integrity.

Formulation Philosophy

DEMELA™ is designed to deliver high brightening efficacy at low active concentrations, allowing it to be formulated without the irritation risks commonly associated with conventional depigmenting agents.

It is typically combined with antioxidants, hydration-supporting agents, soothing components, and barrier-reinforcing actives, enabling visible tone correction to be balanced with skin comfort and long-term tolerance.
This formulation strategy makes DEMELA™ suitable for pigmentation-prone, post-inflammatory, and redness-sensitive skin.

A Molecular Approach to Skin Tone Correction

Uneven skin tone, dark spots, and post-acne marks result from complex biological signaling, including α-MSH stimulation, melanocyte activation, and enzymatic melanin synthesis.

DEMELA™ was developed as a dual-action peptide to cosmetically regulate these processes rather than relying on exfoliation or aggressive suppression alone.
Its mechanism focuses on upstream melanocyte signaling modulation and downstream enzymatic inhibition, supporting gradual, controlled tone normalization.

How DEMELA™ Works

DEMELA™ demonstrates a double blocking effect on melanogenesis:

• Inhibition of MC-1R (α-MSH receptor) signaling, reflected by reduced intracellular cAMP synthesis
• Inhibition of tyrosinase activity, a key enzyme involved in melanin production

In mechanistic evaluations, DEMELA™ showed:

• Significant dose-dependent reduction of cAMP synthesis
• Greater melanin inhibition efficiency at markedly lower concentrations compared to kojic acid
• Higher melanin-inhibiting activity than hydroquinone at the same concentration

This dual modulation supports a visible reduction in hyperpigmentation, redness, and uneven tone, while preserving skin tolerance.

Mechanistic evaluation of DEMELA™ showing modulation of melanocyte signaling and tyrosinase activity (in vitro).